King warned on Embeda VNRs

Share this article:

VNRs for King's ostensibly abuse-resistant pain drug Embeda drew an FDA warning letter.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” boxed warning, and failed to present limitations to the approved indication. Moreover, the letter said King presented misleading claims – among them, about the drug's alleged but clinically unsubstantiated abuse-resistant properties.  DDMAC said King agreed to pull the VNRs in August.

DDMAC demanded the company furnish a list of materials it has pulled, and that it disseminate corrective messaging.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.